NasdaqCM - Delayed Quote • USD
IRADIMED CORPORATION (IRMD)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:03 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | 0.33 | 0.37 | 1.53 | 1.67 |
| Low Estimate | 0.33 | 0.37 | 1.52 | 1.67 |
| High Estimate | 0.34 | 0.37 | 1.54 | 1.67 |
| Year Ago EPS | 0.3 | 0.36 | 1.48 | 1.53 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | 17.16M | 17.92M | 72.81M | 80.1M |
| Low Estimate | 17M | 17.7M | 71.5M | 80.1M |
| High Estimate | 17.33M | 18.15M | 74.12M | 80.1M |
| Year Ago Sales | 15.47M | 16.13M | 65.56M | 72.81M |
| Sales Growth (year/est) | 10.90% | 11.10% | 11.10% | 10.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.28 | 0.31 | 0.36 | 0.4 |
| EPS Actual | 0.3 | 0.36 | 0.43 | 0.39 |
| Difference | 0.02 | 0.05 | 0.07 | -0.01 |
| Surprise % | 7.10% | 16.10% | 19.40% | -2.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.33 | 0.37 | 1.53 | 1.67 |
| 7 Days Ago | 0.33 | 0.37 | 1.53 | 1.67 |
| 30 Days Ago | 0.36 | 0.39 | 1.59 | 1.67 |
| 60 Days Ago | 0.36 | 0.39 | 1.59 | 1.67 |
| 90 Days Ago | 0.41 | 0.4 | 1.67 | 2 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | IRMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 10.00% | -- | -- | 1.60% |
| Next Qtr. | 2.80% | -- | -- | 10.50% |
| Current Year | 3.40% | -- | -- | 5.20% |
| Next Year | 9.20% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 17.50% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 23.97% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Roth Capital: Buy | 8/2/2021 |
| Upgrade | Roth Capital: Neutral to Buy | 7/31/2017 |
| Downgrade | Roth Capital: Buy to Neutral | 10/5/2016 |
| Maintains | Roth Capital: Buy | 4/4/2016 |
| Maintains | Roth Capital: Buy | 6/16/2015 |
| Initiated | Roth Capital: -- | 8/11/2014 |
Related Tickers
KIDS OrthoPediatrics Corp.
30.31
+2.89%
LNSR LENSAR, Inc.
3.2300
+2.87%
PROF Profound Medical Corp.
7.75
-0.39%
IART Integra LifeSciences Holdings Corporation
28.68
-9.33%
MXCT MaxCyte, Inc.
3.9500
+1.80%
LUNG Pulmonx Corporation
7.51
+0.13%
LIVN LivaNova PLC
52.33
-0.82%
NPCE NeuroPace, Inc.
13.98
-0.14%
HYPR Hyperfine, Inc.
0.8300
+2.47%
TMCI Treace Medical Concepts, Inc.
10.97
-2.66%